Spectral Medical
Theranostics: Combining unique diagnostics followed by a targeted therapy.
| CAD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (27 %) | (2 %) | (19 %) | (4 %) | 43 % | 43 % | 204 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (418 %) | (405 %) | (550 %) | (746 %) | (546 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (433 %) | (428 %) | (675 %) | (980 %) | (674 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 11 % | 12 % | 14 % | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Spectral Medical is a pioneering company in the healthcare sector, focusing on theranostic solutions for endotoxic septic shock (ESS), a severe and life-threatening condition caused by systemic inflammation in response to infection. The company operates primarily in the medical diagnostics and therapeutics market, serving hospitals, healthcare providers, and patients affected by ESS. Spectral Medical's business model revolves around combining unique diagnostic tools with targeted therapies to enhance patient outcomes. The company generates revenue through the sale of its diagnostic kits and therapeutic products, as well as through partnerships and collaborations with healthcare institutions. Spectral Medical is committed to reducing the high mortality rates associated with ESS by providing innovative and effective solutions.
Keywords: theranostics, endotoxic septic shock, systemic inflammation, healthcare, diagnostics, targeted therapy, patient outcomes, medical diagnostics, therapeutic products, healthcare providers.